• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

News & Events

  • Print
  • Share
  • E-mail

Public Calendar: November 7-11, 2011

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the Federal Government.

November 7-11, 2011
FDA Official and TitleDateLocationOther FDA ParticipantsNon-FDA ParticipantsSubject
Margaret A. Hamburg, M.D., Commissioner of Food and Drugs11/7/11New York, NYN/AN/ARemarks at FasterCures: “Priming the Pump:  Filling the Therapeutic Pipeline”
Margaret A. Hamburg, M.D., Commissioner of Food and Drugs11/10/11Washington, DCN/AN/ARemarks at 2011 Fourth Annual Conference on Clinical Cancer Research
John M. Taylor, III, J.D., Counselor to the Commissioner11/7/11-11/11/11N/A N/AN/A No Significant Meetings
Deborah M. Autor, Esq., Deputy Commissioner for Global Regulatory Operations and Policy11/7/11-11/11/11N/A N/AN/ANo Significant Meetings
Dara A. Corrigan, Associate Commissioner for Regulatory Affairs11/7/11-11/11/11N/A N/AN/ANo Significant Meetings
Virginia Cox, Associate Commissioner for External Affairs11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Lawrence Deyton, M.S.P.H., M.D., Director, Center for Tobacco Products11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Elizabeth H. Dickinson, Esq., Acting Chief Counsel11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
David Dorsey, J.D., Acting Associate Commissioner for Policy and Planning11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Bernadette Dunham, D.V.M., Ph.D., Director, Center for Veterinary Medicine11/8/11Washington, DCN/AN/ASpeech - CVM Overview at Animal Health Institute's Regulator Day
Jesse Goodman, M.D., M.P.H., Chief Scientist and Deputy Commissioner for Science and Public Health11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Michael M. Landa, Acting Director, Center for Food Safety and Applied Nutrition11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Caroline Lewis, Associate Commissioner for Operations11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Karen Midthun, M.D., Director, Center for Biologics Evaluation and Research11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health11/7/11- 11/11/11N/AN/AN/ANo Significant Meetings
William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research11/8/11-11/9/11Jefferson, ARSeveral FDA staffFDA Science Board Member: Lynn R. Goldman (George Washington University); John R. Bucher (National Toxicology Program); NCTR Science Advisory Board (SAB) members: Cynthia A. Afshari (Amgen, Inc.) (SAB Chair); John D. Baker (Johnson and Johnson PRD); Scott W. Burchiel (University of New Mexico Health Sciences Center); Diana Dow-Edwards (SUNY Downstate Medical Center); Ronald Hines (Medical College of Wisconsin); Paul B. Watkins (The Hamner-UNC Institute for Drug Safety Sciences); Heidi Moline (Union of Concerned Scientists)Annual meeting of the NCTR Science Advisory Board
Stephen Spielberg, M.D., Ph.D., Deputy Commissioner for Medical Products & Tobacco11/8/11New York, NYN/ALesa Mitchell (Ewing Marion Kauffman Foundation); Michael Beckloff (Beckloff Associates, Inc.); Regis B. Kelly (The California Institute for Quantitative Biosciences (QB3), University of California); Scott J. Weir (Institute for Advancing Medical Innovation, University of Kansas Cancer Center)Partnering for Cures Panel: Streamlining Drug Repurposing and Approval
Stephen Spielberg, M.D., Ph.D., Deputy Commissioner for Medical Products & Tobacco11/9/11Boston, MAN/AN/AKeynote Speech at Personalized Medicine Conference
Michael R. Taylor, J.D., Deputy Commissioner for Foods, Office of Foods11/10/11Washington, DCBill HubbardScott Faber (Grocery Manufacturers Association); Joseph Levitt (Hogan Lovells)Food Safety
Jill Hartzler Warner, J.D., Acting Associate Commissioner for Special Medical Programs11/7/11-11/11/11N/AN/AN/ANo Significant Meetings
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research11/8/11Washington, DCN/AJeffrey Drazen (New England Journal of Medicine); Gary Filerman (Atlas Health Foundation); Richard Murray (Merck & Co., Inc.);  Ihor Rak (AstraZeneca)Envisioning a Transformed Clinical Trials Enterprise in the U.S.:  Establishing an Agenda for 2020
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research11/9/11Arlington, VAN/AMark Harrington (Treatment Action Group); Carol Nyirenda (Treatment Advocacy and Literary Campaign)Critical Path to TB Drug Regimens Workshop